Get the Stockscreener App
13.71
2.70%
0.36
After Hours:
13.84
0.13
+0.95%
Promis Neurosciences Inc stock is traded at $13.71, with a volume of 55,352.
It is up +2.70% in the last 24 hours and up +50.16% over the past month.
ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimers disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company applies its thermodynamic, computational discovery platform, ProMIS, and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Compnies product candidates are PMN310, PMN267, and PMN442. Lead product candidate is PMN310, a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 is companies second lead product candidate targeting ALS.
See More
Previous Close:
$13.35
Open:
$13.47
24h Volume:
55,352
Relative Volume:
1.58
Market Cap:
$122.95M
Revenue:
-
Net Income/Loss:
$-40.62M
P/E Ratio:
-0.7064
EPS:
-19.4076
Net Cash Flow:
$-35.63M
1W Performance:
+27.53%
1M Performance:
+50.16%
6M Performance:
+78.28%
1Y Performance:
+26.86%
1-Day Range:
$13.46
$14.15
1-Week Range:
$11.00
$14.30
52-Week Range:
$6.27
$39.75
Promis Neurosciences Inc Stock (PMN) Company Profile
Name
Promis Neurosciences Inc
Sector
Industry
Phone
416-847-6898
Address
SUITE 200, 1920 YONGE STREET, TORONTO
Compare PMN vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PMN
Promis Neurosciences Inc
|
13.71 | 118.01M | 0 | -40.62M | -35.63M | -19.41 |
VRTX
Vertex Pharmaceuticals Inc
|
529.59 | 126.07B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
649.81 | 65.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
916.80 | 57.70B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
313.04 | 40.19B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
189.99 | 39.82B | 742.00K | -1.37B | -1.07B | -7.0731 |
Promis Neurosciences Inc Stock (PMN) Latest News
PMN Initiated Coverage by Cantor Fitzgerald -- Rating Set to Ove - GuruFocus
Wall Street Analysts See a 230.23% Upside in Promis Neurosciences (PMN): Can the Stock Really Move This High? - Yahoo Finance
ProMIS Neurosciences Inc (PMN) Valuation: PE, PB & Fair Value Analysis - TradingKey
Enterprise value to revenue forward of ProMIS Neurosciences Inc. – NASDAQ:PMN - TradingView
ProMIS Neurosciences Inc. Actuals & Estimates (NASDAQ:PMN) - TradingView
PMN Forecast — Price Target — Prediction for 2027 - TradingView
Price to earnings forward of ProMIS Neurosciences Inc. – NASDAQ:PMN - TradingView
Price to sales forward of ProMIS Neurosciences Inc. – NASDAQ:PMN - TradingView
Price to book forward of ProMIS Neurosciences Inc. – NASDAQ:PMN - TradingView
PMN Reiterated by HC Wainwright & Co. -- Price Target Maintained at $18 - GuruFocus
H.C. Wainwright reiterates ProMIS Neurosciences stock rating at buy By Investing.com - Investing.com Nigeria
ProMIS Neurosciences Inc (PMN) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
ProMIS Neurosciences Inc (PMN) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
ProMIS Neurosciences Inc (PMN) Institutional Confidence - TradingKey
ProMIS Neurosciences Inc (PMN) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
ProMIS Neurosciences Inc (PMN) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
ProMIS Neurosciences Inc (PMN) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
ProMIS Neurosciences Inc (PMN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
ProMIS Neurosciences Inc (PMN) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
PMN Q1 2026 Earnings: EPS Beat Surprises as ProMIS Advances PipelinePretax Income Report - newsline.com
PMN Q1 2026 Earnings: Narrowing Losses Amidst Clinical ProgressProfit Inflection Point - newsline.com
ProMIS Neurosciences (PMN) Dips 3.54% as Biotech Stock Tests Key Support ZonePrice Action Signals - newsline.com
All You Need to Know About Promis Neurosciences (PMN) Rating Upgrade to Buy - Yahoo Finance
Wall Street Analysts Think Promis Neurosciences (PMN) Could Surge 231.78%: Read This Before Placing a Bet - Yahoo Finance
ProMIS Neurosciences Inc. (PMN) Q1 2026 Earnings: Narrower-Than-Expected Loss Signals Cost Discipline Amid Pipeline AdvancesAnalyst Drop Coverage - newsline.com
H.C. Wainwright reiterates Buy on ProMIS Neurosciences stock By Investing.com - Investing.com Canada
H.C. Wainwright Maintains ProMIS Neurosciences(PMN.US) With Buy Rating, Maintains Target Price $18 - Moomoo
PMN Q1 2026 Earnings: Narrower-than-Expected Loss Amid Ongoing Clinical DevelopmentROA Comparison - newsline.com
ProMIS Neurosciences Inc Annual Shareholders Meeting Transcript - GuruFocus
PMN Q1 2026 Earnings: EPS Surprises to the Upside Despite Lack of RevenueMargin Guidance - newsline.com
PMN Q1 2026 Earnings: EPS Surprises Positively Amid Continued R&D ProgressShort-Term Outlook - newsline.com
ProMIS Neurosciences (PMN) Faces Bearish Pressure as Shares Slide 3.70%Fibonacci Entry Signals - newsline.com
ProMIS Neurosciences (PMN) Holds Steady Near Support as Biotech Sector Watches Key LevelsSynthetic Short - newsline.com
ProMIS Neurosciences to Participate in Upcoming Conferences in June - The Manila Times
Alzheimer’s drug trial data from ProMIS expected in early Q3 2026 - Stock Titan
PMN Technical Analysis | Trend, Signals & Chart Patterns | PROMIS NEUROSCIENCES INC (NASDAQ:PMN) - ChartMill
PMNProMIS Neurosciences Inc Stock Price and Quote - Finviz
ProMIS Neurosciences (PMN) Slips 5.65% as Shares Test Key Support LevelWave Alternation - newsline.com
PMN Q1 2026 Earnings: Narrower-Than-Expected Loss Highlights Progress in Neurodegenerative PipelineRevenue Breakdown Analysis - The Legal Advocate
PMN Q1 2026 Earnings: Narrower-than-expected Loss; Stock Gains on Pipeline ProgressPretax Income Report - Newser
Yu Fan's ProMIS Neurosciences Inc(PMN) Holding History - GuruFocus
ProMIS Neurosciences (PMN) director granted 16,500 options at $10.77 strike price - Stock Titan
ProMIS Neurosciences (PMN) director granted options on 16,500 shares - Stock Titan
ProMIS Neurosciences (PMN) CEO awarded 160,000 options at $10.77 strike - Stock Titan
ProMIS Neurosciences (PMN) director awarded long-dated stock options - Stock Titan
ProMIS Neurosciences (PMN) awards CSO 50,000 options vesting over 4 years - Stock Titan
Executive at ProMIS (PMN) receives 18,167 stock options expiring 2036 - Stock Titan
ProMIS Neurosciences (PMN) director receives 16,500 stock options grant - Stock Titan
ProMIS Neurosciences (PMN) CDO awarded 50,000 stock options - Stock Titan
Director at ProMIS Neurosciences (PMN) receives new option grants as board compensation - Stock Titan
PMN Q1 2026 Earnings: Narrowed EPS Surprise Drives Positive Stock ReactionDividend Earnings Report - The Legal Advocate
Promis Neurosciences Inc Stock (PMN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Promis Neurosciences Inc Stock (PMN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Williams Eugene | Director |
Mar 05 '26 |
Buy |
24.40 |
2,000 |
48,800 |
12,397 |
| Williams Eugene | Director |
Mar 04 '26 |
Buy |
24.00 |
2,000 |
48,000 |
10,397 |
| Williams Eugene | Director |
Mar 02 '26 |
Buy |
22.53 |
1,000 |
22,530 |
7,397 |
| Williams Eugene | Director |
Mar 03 '26 |
Buy |
21.89 |
1,000 |
21,890 |
8,397 |
| Kaplan Johanne | Chief Development Officer |
Feb 19 '26 |
Buy |
15.35 |
1,629 |
25,005 |
3,941 |
| ABG Management Ltd. | 10% Owner |
Feb 03 '26 |
Buy |
12.13 |
700,741 |
8,499,988 |
943,090 |
| Milbury Max A. | Principal Accounting Officer |
Oct 03 '25 |
Buy |
0.49 |
30,392 |
14,929 |
45,389 |
0.05%
0.74%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):